Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
Saved in:
| Title: | Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. |
|---|---|
| Authors: | Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Beeram M; South Texas Accelerated Research Therapeutics, San Antonio, TX, United States., Beck JT; Department of Medical Oncology and Hematology, Highlands Oncology, Springdale, AR, United States., Conlin A; Providence Cancer Center, Portland, OR, United States., Dees EC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Puhalla SL; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States., Rexer BN; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States., Burris HA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, United States., Jhaveri K; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.; Department of Medicine, Weil Cornell Medical College, New York, NY, United States., Helsten T; Moores Cancer Center, University of California San Diego, San Diego, CA, United States., Becerra C; Texas Oncology, Dallas, TX, United States., Kalinsky K; Department of Medicine, Columbia University, New York, NY, United States.; Department of Hematology/Oncology, Emory University Winship Cancer Institute, Atlanta, GA, United States., Moore KN; Stevenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.; Sarah Cannon Research Institute, Nashville, TN, United States., Manuel AM; Eli Lilly and Company, Indianapolis, IN, United States., Lithio A; Eli Lilly and Company, Indianapolis, IN, United States., Price GL; Eli Lilly and Company, Indianapolis, IN, United States., Chapman SC; Eli Lilly and Company, Indianapolis, IN, United States., Litchfield LM; Eli Lilly and Company, Indianapolis, IN, United States., Goetz MP; Department of Oncology, Mayo Clinic, Rochester, MN, United States.; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2022 Feb 10; Vol. 11, pp. 810023. Date of Electronic Publication: 2022 Feb 10 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2021.810023 |
